COVID-19 Resources

Stay up to date on the latest news and information on COVID-19 with resources including latest CDC/WHO/AAFP recommendations, payment information, telemedicine updates, office preparedness updates and more for Family Physicians.

July 2022


COVID-19: Novavax Vaccine, Adjuvanted — New Codes

The FDA authorized emergency use of the Novavax COVID-19 vaccine, Adjuvanted for the prevention of COVID-19 disease in patients 18 years and older.

CMS issued 3 new CPT codes effective July 13, 2022:

Code 91304 for vaccine product:

  • Long descriptor: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use
  • Short descriptor: SARSCOV2 VAC 5MCG/0.5ML IM

Code 0041A for vaccine administration, first dose:

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; first dose
  • Short descriptor: ADM SARSCOV2 5MCG/0.5ML 1ST

Code 0042A for vaccine administration, second dose:

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; second dose
  • Short descriptor: ADM SARSCOV2 5MCG/0.5ML 2ND

Visit the COVID-19 Vaccine Provider Toolkit for more information, and get the most current list of billing codes, payment allowances, and effective dates. Note: You may need to refresh your browser if you recently visited this webpage.


Coronavirus (COVID-19) Update: FDA Authorizes Pharmacists to Prescribe Paxlovid with Certain Limitations | FDA

New Prescribing Authority Could Improve Access for Some Patients at High Risk for Severe COVID-19

For Immediate Release: July 06, 2022

Today, the U.S. Food and Drug Administration revised the Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir and ritonavir), to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid. 

“The FDA recognizes the important role pharmacists have played and continue to play in combatting this pandemic,” said Patrizia Cavazzoni, M.D., director for the FDA’s Center for Drug Evaluation and Research. “Since Paxlovid must be taken within five days after symptoms begin, authorizing state-licensed pharmacists to prescribe Paxlovid could expand access to timely treatment for some patients who are eligible to receive this drug for the treatment of COVID-19.” 

When testing positive for COVID-19, patients should first consider seeking care from their regular health care provider or locating a Test-to-Treat site in their area. While this action allows state-licensed pharmacists to prescribe Paxlovid with certain limitations as described below, community pharmacies not already participating as a Test-to-Treat site can decide if or how they will offer this service to patients.  

Patients who have tested positive for COVID-19 and are seeking to determine their eligibility for receiving Paxlovid at locations where prescribing by state-licensed pharmacists is available should bring the following information to ensure that the state-licensed pharmacist has sufficient information to determine their eligibility to receive Paxlovid:

  • Electronic or printed health records less than 12 months old, including the most recent reports of laboratory blood work for the state-licensed pharmacist to review for kidney or liver problems. State-licensed pharmacists could also receive this information through a consult with the patient’s health care provider.
  • A list of all medications they are taking, including over-the-counter medications so the state-licensed pharmacist can screen for drugs with potentially serious interactions with Paxlovid.

Under the limitations outlined in the authorization, the state-licensed pharmacist should refer patients for clinical evaluation with a physician, advanced practice registered nurse, or physician assistant licensed or authorized under state law to prescribe drugs, if any of the following apply:

  • Sufficient information is not available to assess renal and hepatic function.
  • Sufficient information is not available to assess for a potential drug interaction.
  • Modification of other medications is needed due to a potential drug interaction.
  • Paxlovid is not an appropriate therapeutic option based on the current Fact Sheet for Healthcare Providers or due to potential drug interactions for which recommended monitoring would not be feasible.

Paxlovid is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 viral testing, who are at high risk for progression to severe COVID-19, including hospitalization or death. Patients in the authorized population who report a positive home test result from a rapid antigen diagnostic test, or a positive PCR test, to their provider are eligible for Paxlovid under the EUA. Confirmation of a positive home rapid antigen diagnostic test with additional direct SARS-CoV-2 viral testing, such as a PCR, is not required. Antibody tests are not considered to be direct SARS-CoV-2 viral tests.


COVID-19: FDA Authorizes Pharmacists to Prescribe PAXLOVID with Certain Limits 

The FDA issued an emergency use authorization (EUA) for PAXLOVID (nirmatrelvir co-packaged with ritonavir) for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients at high risk for progression to severe COVID-19, including hospitalization or death. On July 6, the FDA revised the EUA to let pharmacists prescribe and dispense PAXLOVID to eligible patients without seeing a doctor or other clinician. 

More Information:

Related Information


Long COVID: Use ICD-10 Code U09.9

For a post COVID-19 condition, unspecified, like Long COVID, use code DX U09.9. Add other codes for conditions related to the COVID-19 infection, like R50.9 for fever. 

For a current COVID-19 infection, use code DX U07.1. Don’t use code DX U09.9.  

For a current COVID-19 infection and conditions from a previous COVID-19 infection, use code U09.9 with code DX U07.1. Add other codes for conditions related to the COVID-19 infection, like R06.02 for shortness of breath. 

For more information, see pages 30-31 of ICD-10-CM Official Guidelines for Coding and Reporting: Fiscal Year 2022 (PDF).

June 2022


COVID-19: Pfizer-BioNTech Vaccines for Children as Young as 6 Months — New Codes

On June 17, 2022, the FDA amended the Pfizer-BioNTech COVID-19 vaccine emergency use authorization (PDF) to authorize use for all patients 6 months – 4 years old. Get important vial and dosing information. CMS issued new CPT codes effective June 17, 2022:

Code 91308 for vaccine product:

  • Long descriptor: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
  • Short descriptor: SARSCOV2 VAC 3 MCG TRS-SUCR

Code 0081A for vaccine administration, first dose:

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
  • Short descriptor: ADM SARSCV2 3MCG TRS-SUCR 1

Code: 0082A for vaccine administration, second dose:

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose
  • Short descriptor: ADM SARSCV2 3MCG TRS-SUCR 2

Code 0083A for vaccine administration, third dose:

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose
  • Short descriptor: ADM SARSCV2 3MCG TRS-SUCR 3

Visit the COVID-19 Vaccine Provider Toolkit for more information, and get the most current list of billing codes, payment allowances, and effective dates. Note: you may need to refresh your browser if you recently visited this webpage.

COVID-19: Moderna Vaccines for Children as Young as 6 Months — New Codes

The FDA amended the Moderna COVID-19 vaccine emergency use authorization (PDF) to authorize use for all patients 6 months – 17 years old. 

CMS issued 7 new CPT codes effective June 17, 2022:

Code 91311 for vaccine product:

  • Long descriptor: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use
  • Short descriptor: SARSCOV2 VAC 25MCG/0.25ML IM

Code 0111A for vaccine administration, first dose:

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose
  • Short descriptor: ADM SARSCOV2 25MCG/0.25ML1ST

Code 0112A for vaccine administration, second dose:

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose
  • Short descriptor: ADM SARSCOV2 25MCG/0.25ML2ND

Code 0113A for vaccine administration, third dose:

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose
  • Short descriptor: ADM SARSCOV2 25MCG/0.25ML3RD

Code 0091A for vaccine administration, first dose:

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years
  • Short descriptor: ADM SARSCOV2 50 MCG/.5 ML1ST

Code 0092A for vaccine administration, second dose:

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years
  • Short descriptor: ADM SARSCOV2 50 MCG/.5 ML2ND

Code 0093A for vaccine administration, third dose:

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years
  • Short descriptor: ADM SARSCOV2 50 MCG/.5 ML3RD

Visit the COVID-19 Vaccine Provider Toolkit for more information, and get the most current list of billing codes, payment allowances, and effective dates. Note: You may need to refresh your browser if you recently visited this webpage.

May 2022


FDA New Checklist for Paxlovid

The FDA released a new checklist to help clinicians determine which patients are eligible for Paxlovid, an oral antiviral for mild to moderate COVID-19 in adults and some pediatric patients who are at high risk for severe COVID-19. The agency also updated a Paxlovid fact sheet with more specific recommendations. Learn more.


COVID-19: New Administration Code for Pfizer Pediatric Vaccine Booster Dose

On May 17, 2022, the FDA amended the Pfizer-BioNTech COVID-19 vaccine emergency use authorization (PDF) to authorize the use of a single booster pediatric dose (orange cap) for all patients 5–11 years oldCMS issued a new code, effective May 17, 2022, for the vaccine administration:

Code: 0074A

  • Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation
  • Short descriptor: ADM SARSCV2 10MCG TRS-SUCR B

For more information, visit the COVID-19 Provider Toolkit, and get the most current list of billing codes, payment allowances, and effective dates. (Note: you may need to refresh your browser if you recently visited these webpages).


CDC Strengthens Recommendations and Expands Eligibility for COVID-19 Booster Shots

The CDC is expanding eligibility of COVID-19 vaccine booster doses to everyone 5 years of age and older. CDC now recommends that children ages 5 through 11 years should receive a booster shot 5 months after their initial Pfizer-BioNTech vaccination series. Since the pandemic began, more than 4.8 million children ages 5 through 11 have been diagnosed with COVID-19, 15,000 have been hospitalized and, tragically, over 180 have died. As cases increase across the country, a booster dose will safely help restore and enhance protection against severe disease.

In addition, the CDC is strengthening its recommendation that those 12 and older who are immunocompromised and those 50 and older should receive a second booster dose at least 4 months after their first. Over the past month we have seen steady increases in cases, with a steep and substantial increase in hospitalizations for older Americans. While older Americans have the highest coverage of any age group of first booster doses, most older Americans received their last dose (either their primary series or their first booster dose) many months ago, leaving many who are vulnerable without the protection they may need to prevent severe disease, hospitalization, and death.

Whether it is your first booster, or your second, if you haven’t had a vaccine dose since the beginning of December 2021 and you are eligible, now is the time to get one.

Read the Statement Here

April 2022


Updated COVID Vaccination Resources from the CDC:

New information on Covid-19 testing (updated flier)

What to Expect After Getting a COVID-19 Vaccine (updated flier)

Modern COVID-19 Vaccine: Vaccine Preparation and Administration Summary (up-to-date guidance)

Pfizer-BioNTech COVID-19 Vaccine: 12 Years of Age and Older – Preparation and Administration Summary (up-to-date guidance)

March 2022


COVID-19 Monoclonal Antibodies: Revised Emergency Use Authorization for EVUSHELD

On February 24, the FDA revised the emergency use authorization for tixagevimab co-packaged with cilgavimab (EVUSHELD™) to change the initial dose for the authorized use as pre-exposure prophylaxis of COVID-19 in certain adults and pediatric patients. For more information about dosage and administration, including information about dosing for patients who got the original lower dose, review the fact sheet (ZIP).

CMS created new code, Q0221, effective February 24:

  • Long Descriptor: Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg
  • Short Descriptor: Tixagev and cilgav, 600mg

Use the existing administration codes — M0220 and M0221.

Visit the COVID-19 Monoclonal Antibodies webpage for more information. Note: you may need to refresh your browser if you recently visited this webpage.

January 2022


COVID-19 Vaccine Codes: Pfizer Pre-Diluted Vaccine for Patients Ages 12+ & Third Dose for Immunocompromised Patients Ages 5-11

On January 3, the FDA:

  • Authorized an additional pre-diluted formulation (gray cap) for patients 12 years and older
  • Amended the Pfizer-BioNTech COVID-19 vaccine (PDF) emergency use authorization to allow for third pediatric doses (orange cap) for 5–11-year-old solid organ transplant patients or patients with a similar level of immunocompromise

Get the most current list of billing codes, payment allowances, and effective dates.

More Information:


CDC updates COVID-19 Testing:

What You Need to Know (updated 12/29) with videos/posters to share with patients and families


COVID-19 Vaccine & Monoclonal Antibody Products: Changes for MA Plan Claims Started January 1

If you vaccinate or administer monoclonal antibody treatment to patients enrolled in Medicare Advantage (MA) plans on or after January 1, 2022, submit claims to the MA Plan. Original Medicare won’t pay these claims.

More Information:

September 2021


Immediate Authorization of COVID-19 Booster Shots For Marylanders

Governor Larry Hogan recently issued the following statement after the U.S. Centers for Disease Control and Prevention (CDC) gave final approval for Pfizer COVID-19 booster shots:

“While this action was long overdue, I am glad that the federal government has finally approved booster shots for seniors and high-risk individuals. It is a significant step toward providing additional protection for our most vulnerable residents and supports the data-based decision we made earlier this month to move ahead on booster shots for seniors in congregate settings.

“Maryland has already administered more than 50,000 additional doses, and we have both the supply and the capacity to provide a booster shot to anyone who needs one. We have mobilized a robust network of vaccination providers, including pharmacies, primary care providers, mobile clinics, community health centers, and local health departments.”  READ MORE

August 2021


COVID-19 Monoclonal Antibody EUA Updates: casirivimab/imdevimab

CMS posted technical updates to the Monoclonal Antibody COVID-19 Infusion and COVID-19 Vaccines and Monoclonal Antibodies webpages to reflect updates to the Emergency Use Authorization (EUA) for casirivimab and imdevimab, a COVID-19 monoclonal antibody. 


Impact of the PHE on Telehealth: Comparative Billing Report in August

In late August, CMS will issue a Special Edition Comparative Billing Report (CBR) on the impact of the Public Health Emergency (PHE) on Part B claims for telehealth. Use the data-driven report to compare your billing practices during the PHE with those of your peers in your state and across the nation.

CBRs aren’t publicly available. Look for an email from cbrpepper.noreply@religroupinc.com to access your report. Update your email address in the Provider Enrollment, Chain, and Ownership System to ensure delivery. 

More Information:


CMS Expands Medicare Payments for At-Home COVID-19 Vaccinations

As part of the Biden-Harris Administration’s ongoing commitment to increasing access to vaccinations and improving health equity, the Centers for Medicare & Medicaid Services (CMS) is expanding opportunities for people to receive COVID-19 vaccinations in their home. To ensure Medicare beneficiaries who have difficulty leaving their homes or are otherwise hard-to-reach can receive the vaccination, healthcare providers can now receive additional payments for administering vaccines to multiple residents in one home setting or communal setting of a home.   

August 24th’s announcement aims to further boost the administration of COVID-19 vaccination – including second and third doses – in smaller group homes, assisted living facilities, and other group living situations by allowing vaccine providers to receive the increased payment up to five times when fewer than ten Medicare beneficiaries get the vaccine on the same day in the same home or communal setting. This policy will help ensure that at-risk patients in smaller settings have the same opportunities as others to receive the vaccination. READ MORE


COVID-19 Vaccines Additional Doses: Codes & Payment

The FDA amended the emergency use authorizations (EUAs) for both the Pfizer BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine to allow for an additional dose in certain immunocompromised people.

Effective August 12, 2021, CMS will pay to administer additional doses of COVID-19 vaccines consistent with the FDA EUAs, using CPT code 0003A for the Pfizer vaccine and CPT code 0013A for the Moderna vaccine. We’ll pay the same amount to administer this additional dose as we did for other doses of the COVID-19 vaccine (approximately $40 each).

We’ll hold and then process all claims with these codes after we complete claims system updates (no later than August 27).

Learn more about Medicare COVID-19 vaccine:


Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals

The U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is scheduled to meet Friday to discuss further clinical recommendations regarding immunocompromised individuals. Today’s action does not apply to people who are not immunocompromised.

“The country has entered yet another wave of the COVID-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease. After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna Vaccines,” said Acting FDA Commissioner Janet Woodcock, M.D. “Today’s action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19. As we’ve previously stated, other individuals who are fully vaccinated are adequately protected and do not need an additional dose of COVID-19 vaccine at this time. The FDA is actively engaged in a science-based, rigorous process with our federal partners to consider whether an additional dose may be needed in the future.” READ MORE


COVID-19 Vaccines for Moderately to Severely Immunocompromised People

What You Need to Know:

  • People who are moderately to severely immunocompromised are especially vulnerable to COVID-19 because they are more at risk of serious, prolonged illness.
  • People who have compromised immune systems may benefit from an additional dose to make sure they have enough protection against COVID-19.
  • CDC recommends people who are moderately to severely immunocompromised should receive an additional dose of mRNA COVID-19 vaccine after the initial 2 doses.

CDC recommends that people with moderately to severely compromised immune systems receive an additional dose of mRNA COVID-19 vaccine at least 28 days after a second dose of Pfizer-BioNTech COVID-19 vaccine or Moderna COVID-19 vaccine.

CDC does not recommend additional doses or booster shots for any other population at this time.

July 2021


Confronting COVID-19 Vaccine Misinformation

View shareable resources and the Advisory from the U.S. Surgeon General about COVID-19 misinformation.
View Resources >


Clinical Considerations: Myocarditis and Pericarditis after Receipt of mRNA COVID-19 Vaccines Among Adolescents and Young Adults

Since April 2021, increased cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna), particularly in adolescents and young adults. There has not been a similar reporting pattern observed after receipt of the Janssen COVID-19 Vaccine (Johnson & Johnson).
Read More

June 2021


Pfizer COVID-19 Vaccine Provider Updates

The Maryland Department of Health recently released updated guidance for COVID vaccines regarding the Pfizer vaccine provider qualifications and process.


COVID-19 Vaccine Patient Education | Resources to help answer your patients’ questions

Customize and use any of the Encouraging COVID-19 Vaccinations: Sample Patient Education Messages in your patient portal, newsletters or emails.


Use the Debunking Common COVID-19 Vaccine Myths article on familydoctor.org to correct misconceptions your patients might have, like: 

  • The COVID-19 vaccines were developed too fast to be safe.
  • There weren’t enough participants in clinical trials to declare the vaccines safe.
  • I won’t need to wear a mask after I am vaccinated.

READ MORE

May 2021


New MDH COVID-19 Vaccine Resource Guide for Primary Care

In partnership with Maryland Department of Health and Maryland Primary Care Program, we are happy to share the newly developed COVID-19 Vaccine Communication and Outreach Strategies in Primary Care guide and the following message from the MDH Primary Care Vaccine Program Team:

As COVID-19 vaccine demand decreases, it will take more outreach and one-on-one conversations at your practice to work with patients to accept the vaccine. We hope you can use this document as a guide for those initiatives at your practice.

In the document, you’ll find: 

  • Positive messaging for the COVID-19 vaccine
  • Ways to respond to common reasons for vaccine hesitancy
  • Outreach strategies for getting people in for vaccine appointments and examples from successful practices
  • And more!

April 2021


SPREAD THE WORD

As of Monday, April 19, 2021, every person 16 years and older in the United States is now eligible to receive a COVID-19 vaccine. You can help spread the word so every adult knows they are now eligible. Use the NEW COVID-19 Community Corps Social Media Toolkit to spread the word about expanded eligibility.


HHS Campaigns

HHS just launched a COVID-19 Public Education Campaign, We Can Do This, which is a national initiative to increase public confidence in and uptake of COVID-19 vaccines while reinforcing basic prevention measures such as mask wearing and social distancing.

March 2021


COVID-19 now included in the Immunization Division’s

Vaccine Confidence resources:

  • Communicate with Confidence
  • Talking with Patients about Vaccines
  • A convenient downloadable one-pager of vaccine resources, to help providers talk to patients about vaccines.

Features include:

  • Articles – Videos – Apps – Social Media
  • Vaccine Conversations – Vaccine Safety – COVID-19 Vaccines
  • Specific Populations – Handouts for Patients/Staff

ACCESS FULL RESOURCES HERE

February 2021


COVID-19: Revised Clinician Codes Accepted with CS Modifier

Effective March 18, 2020, the Families First Coronavirus Response Act requires Medicare Part B to cover beneficiary cost-sharing for provider visits when a COVID-19 diagnostic test is administered or ordered. CMS updated the list of codes (ZIP) that physicians and non-physician practitioners can use with the Cost-Sharing (CS) modifier.

For dates of service on or after January 1, 2021, through the end of the public health emergency, we’ll accept these codes with the CS modifier:

HCPCS codes G2250, G2251, and G2252
CPT codes 98970, 98971, and 98972 (These replace HCPCS codes G2061 – G2063, which are accepted for services provided in 2020)  
CPT codes 98966, 98967, and 98968 are accepted for services with the CS modifier provided on or after March 18, 2020.

More information about cost-sharing: Medicare Fee-For-Service (FFS) Response to the Public Health Emergency on the Coronavirus (COVID-19) (PDF) MLN Matters Article

December 2020


Home For The Holidays: Governor Hogan Announces New Travel Orders, $180 Million More in Economic Relief

Governor Larry Hogan and state health officials recently took a series of actions to slow the spread of COVID-19 during the holiday season, including new testing and quarantine requirements for travel, and a new public health advisory to limit gatherings. In addition, the governor announced an additional $180 million in emergency economic relief, including more help for bars and restaurants, as well as a boost in the Temporary Cash Assistance benefit.

“Our strongest defense against this virus continues to be the cooperation and the vigilance of the people of Maryland,” said Governor Hogan. “However, this holiday season could present perhaps our toughest challenge yet. Our message today is simple: you are safer at home for the holidays this year. Making difficult sacrifices during these next few weeks will absolutely help to keep your family, loved ones, and your fellow Marylanders safe.” 

Read More

November 2020


CDC Digital Media Toolkit: 2020-21 Flu Season

Help spread the word on the importance of getting a flu vaccine by using the CDC’s recently released digital media toolkit for the 2020-21 flu season. FDA also released multiple reasons why it is important to get your flu vaccine, especially during the COVID-19 pandemic.


New Resource for COVID-19: CDC/IDSA Real-Time Learning Network

The American Academy of Family Physicians has been selected by the CDC as a collaborator in the COVID-19 Real-Time Learning Network (RTLN). The RTLN is a collaborative effort led by the Infectious Diseases Society of America to provide access to the latest information on fighting COVID-19 by bringing together the many health care disciplines fighting this pandemic to share resources and best practices, and ultimately decrease the impact of COVID-19 and save lives.  The goal of the network is to bring value, support, and guidance to healthcare providers treating COVID-19 patients through education, communication and outreach. READ MORE

October 2020


CMS Announces New Repayment Terms for Medicare Loans Made to Providers During COVID-19

New recoupment terms allow providers and suppliers one additional year to start loan payments

CMS announced amended terms for payments issued under the Accelerated and Advance Payment (AAP) Program as required by recent action by President Trump and Congress. This Medicare loan program allows CMS to make advance payments to providers, which are typically used in emergency situations. Under the Continuing Appropriations Act, 2021 and Other Extensions Act, repayment will now begin one year from the issuance date of each provider or supplier’s accelerated or advance payment. CMS issued $106 billion in payments to providers and suppliers in order to alleviate the financial burden health care providers faced while experiencing cash flow issues in the early stages of combating the Coronavirus Disease 2019 (COVID-19) public health emergency.

“In the throes of an unprecedented pandemic, providers and suppliers on the frontlines needed a lifeline to help keep them afloat,” said CMS Administrator Seema Verma. “CMS’ advanced payments were loans given to providers and suppliers to avoid having to close their doors and potentially causing a disruption in service for seniors. While we are seeing patients return to hospitals and doctors providing care we are not yet back to normal,” she added.

CMS expanded the AAP Program on March 28, 2020, and gave these loans to health care providers and suppliers in order to combat the financial burden of the pandemic. CMS successfully paid more than 22,000 Part A providers, totaling more than $98 billion in accelerated payments. This included payments to Part A providers for Part B items and services they furnished. In addition, more than 28,000 Part B suppliers, including doctors, non-physician practitioners, and durable medical equipment suppliers received advance payments totaling more than $8.5 billion.

Providers were required to make payments starting in August of this year, but with this action, repayment will be delayed until one year after payment was issued. After that first year, Medicare will automatically recoup 25% of Medicare payments otherwise owed to the provider or supplier for 11 months. At the end of the 11-month period, recoupment will increase to 50% for another 6 months. If the provider or supplier is unable to repay the total amount of the AAP during this time-period (a total of 29 months), CMS will issue letters requiring repayment of any outstanding balance, subject to an interest rate of 4%.

The letter also provides guidance on how to request an Extended Repayment Schedule (ERS) for providers and suppliers who are experiencing financial hardships. An ERS is a debt installment payment plan that allows a provider or supplier to pay debts over the course of 3 years, or, up to 5 years in the case of extreme hardship. Providers and suppliers are encouraged to contact their MAC for information on how to request an ERS. To allow even more flexibility in paying back the loans, the $175 billion issued in Provider Relief funds can be used towards repayment of these Medicare loans. CMS will be communicating with each provider and supplier in the coming weeks as to the repayment terms and amounts owed as applicable for any accelerated or advance payment issued.

For More Information:

Fact Sheet
FAQs

© Copyright 2022 MDAFP or MDAFP Foundation • 210 Green Bay Rd • Thiensville, WI 53092 • Phone: 888-894-2606 • E-Mail: info@mdafp.org